IDNA Performance — iShares Genomics Immunology and Healthcare ETF
Data updated: 2026-10-13
IDNA returned +24.06% year to date and +54.24% over one year to Jul 2026. Annualised returns are +11.79% over 3 years and −7.47% over 5 years. The fund beat its Global Health Care Equity category average: $100 invested three years ago grew to $140, against $127 for the category, and to $154 over one year, against $123. Volatility over the past three years was 23.26% a year. In the 12 months to Jul 2026 the fund took in a net $25.5M, and assets reached $190.86M.
IDNA Growth of $100
What $100 invested in iShares Genomics Immunology and Healthcare ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Global Health Care Equity category average over the same months.
| Period | IDNA | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $154 | $123 |
| 3 years (Aug 2023 – Jul 2026) | $140 | $127 |
| 5 years (Aug 2021 – Jul 2026) | $68 | $103 |
| Since data start (Aug 2019 – Jul 2026) | $124 | $159 |
IDNA Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +24.06% |
| 1 year | +54.24% |
| 3 years (annualised) | +11.79% |
| 5 years (annualised) | −7.47% |
IDNA Annual Returns
Calendar-year total returns of iShares Genomics Immunology and Healthcare ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +24.06% |
| 2025 | +17.36% |
| 2024 | −0.98% |
| 2023 | −7.75% |
| 2022 | −42.10% |
| 2021 | −4.01% |
| 2020 | +54.49% |
| 2019 (Aug–Dec) | +8.93% |
IDNA Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +9.1% | +8.8% | −7.1% | +1.9% | +1.7% | +12.9% | −3.9% | — | — | — | — | — |
| 2025 | +0.9% | −1.2% | −9.2% | +3.1% | −4.1% | +2.3% | +3.1% | +4.5% | +6.9% | +7.3% | +8.5% | −4.3% |
| 2024 | −3.6% | +8.8% | −0.4% | −6.3% | +5.2% | −2.0% | +7.3% | +0.6% | −1.7% | −1.7% | +2.2% | −8.0% |
| 2023 | +6.9% | −10.7% | −3.1% | +0.7% | +1.9% | −2.2% | +2.7% | −6.0% | −9.4% | −11.2% | +14.0% | +12.3% |
| 2022 | −17.0% | −4.1% | −1.3% | −13.4% | −3.7% | +1.4% | +9.2% | −6.4% | −10.9% | +3.1% | +3.6% | −10.5% |
| 2021 | +9.4% | −6.7% | −2.8% | +5.0% | −2.1% | +10.9% | −3.7% | +7.5% | −5.8% | −2.3% | −4.4% | −6.9% |
| 2020 | −6.4% | +4.2% | −8.1% | +18.2% | +13.6% | +5.7% | −1.5% | +2.5% | +1.7% | −2.7% | +18.1% | +3.0% |
| 2019 | — | — | — | — | — | — | — | −6.7% | −5.1% | +5.9% | +12.4% | +3.4% |
IDNA Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 23.26%
- 3-year Sharpe ratio: 0.31 (vs 4.5% risk-free rate)
- Best month: +13.99% (Nov 2023)
- Worst month: −11.15% (Oct 2023)
IDNA Fund Flows
Monthly money in and out of iShares Genomics Immunology and Healthcare ETF, from SEC Form N-PORT.
- 12-month net flow: $25.5M
- 12-month gross sales (incl. reinvestments): $33.9M
- Sales ÷ redemptions: 4.05×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $5.0M | $0 | $5.0M |
| Jun 2026 | $9.7M | $0 | $9.7M |
| May 2026 | $0 | $0 | $0 |
| Apr 2026 | $7.7M | $0 | $7.7M |
| Mar 2026 | $3.0M | $0 | $3.0M |
| Feb 2026 | $3.1M | $0 | $3.1M |
| Jan 2026 | $0 | $0 | $0 |
| Dec 2025 | $4.0M | $0 | $4.0M |
| Nov 2025 | $0 | $5.2M | −$5.2M |
| Oct 2025 | $1.2M | $0 | $1.2M |
| Sep 2025 | $0 | $0 | $0 |
| Aug 2025 | $0 | $3.2M | −$3.2M |
IDNA Assets Under Management
Net assets of iShares Genomics Immunology and Healthcare ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $190.86M |
| 2026-04-30 | $160.48M |
| 2026-01-31 | $142.81M |
| 2025-10-31 | $128.18M |
| 2025-07-31 | $109.10M |
| 2025-04-30 | $111.77M |
| 2025-01-31 | $123.10M |
| 2024-10-31 | $137.76M |
| 2024-07-31 | $140.40M |
| 2024-04-30 | $132.02M |
| 2024-01-31 | $123.29M |
| 2023-10-31 | $109.69M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.